Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 9/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL7716649 | 0.78 | GABBR2 (0.53) | SRCCYP1A2LMNAMAPTTHRB | |
| SCHEMBL7717080 | 0.78 | MAPT (0.50) | LMNAMAPTNPSR1POLBPBRM1 | |
| SCHEMBL28294961 | 0.75 | PBRM1 (0.45) | LMNASMN1; SMN2ESR1ESR2PBRM1 | |
| SCHEMBL7007862 | 0.74 | ESR1 (0.47) | CYP1A2SMN1; SMN2NPSR1ESR1ESR2 | |
| SCHEMBL781228 | 0.71 | ACP3 (0.46) | SRCCYP1A2LMNAMAPTTHRB | |
| SCHEMBL7886991 | 0.71 | ESR1 (0.46) | CYP1A2LMNASMN1; SMN2NPSR1ESR1 | |
| SCHEMBL28576221 | 0.71 | ESR1 (0.46) | CYP1A2LMNASMN1; SMN2NPSR1ESR1 | |
| Butane SCHEMBL11091747 | 0.71 | TRPA1 (0.38) | LMNAMAPTPBRM1 | |
| SCHEMBL2223719 | 0.70 | GABBR2 (0.59) | SRCCYP1A2LMNAMAPTTHRB | |
| SCHEMBL27930776 | 0.70 | GABBR2 (0.59) | CYP1A2LMNAMAPTTHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |